• Consensus Rating: Moderate Buy
  • Consensus Price Target: $46.38
  • Forecasted Upside: 93.23%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$24.00
▲ +1.11 (4.85%)

This chart shows the closing price for ANAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AnaptysBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANAB

Analyst Price Target is $46.38
▲ +93.23% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is $46.38, with a high forecast of $80.00 and a low forecast of $21.00. The average price target represents a 93.23% upside from the last price of $24.00.

This chart shows the closing price for ANAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 polled investment analysts is to moderate buy stock in AnaptysBio. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/31/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2024WedbushReiterated RatingOutperform ➝ Outperform$34.00Low
4/16/2024Leerink PartnrsReiterated RatingOutperformLow
4/16/2024SVB LeerinkInitiated CoverageOutperform$47.00Low
4/11/2024Wells Fargo & CompanyInitiated CoverageOverweight$56.00Low
4/1/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$30.00 ➝ $28.00Low
3/12/2024WedbushUpgradeNeutral ➝ Outperform$20.00 ➝ $34.00Low
2/26/2024BTIG ResearchInitiated CoverageBuy$55.00Low
2/21/2024Stifel NicolausInitiated CoverageBuy$50.00Low
2/16/2024Piper SandlerInitiated CoverageOverweight$80.00Low
11/29/2023WedbushReiterated RatingNeutral ➝ Neutral$20.00Low
11/3/2023WedbushBoost TargetNeutral ➝ Neutral$18.00 ➝ $20.00Low
11/2/2023UBS GroupLower TargetNeutral ➝ Neutral$28.00 ➝ $21.00Low
8/8/2023WedbushLower TargetNeutral ➝ Neutral$29.00 ➝ $26.00Low
5/22/2023JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$31.00 ➝ $30.00Low
5/18/2023TD CowenInitiated CoverageOutperformLow
5/12/2023GuggenheimBoost Target$44.00 ➝ $45.00Low
4/12/2023JPMorgan Chase & Co.Lower TargetUnderweight$32.00 ➝ $31.00Low
1/6/2023Raymond JamesDowngradeOutperform ➝ Market PerformLow
11/18/2022JPMorgan Chase & Co.Boost TargetUnderweight$24.00 ➝ $32.00Low
11/9/2022WedbushBoost Target$21.00 ➝ $32.00Low
11/9/2022Raymond JamesBoost TargetOutperform$30.00 ➝ $38.00Low
11/1/2022GuggenheimUpgradeNeutral ➝ Buy$44.00Low
9/19/2022HC WainwrightReiterated RatingBuy$35.00Low
9/13/2022Truist FinancialDowngradeBuy ➝ Hold$50.00 ➝ $28.00Low
9/6/2022WedbushLower Target$24.00Low
9/1/2022Raymond JamesLower Target$35.00 ➝ $30.00Low
8/31/2022Raymond JamesInitiated CoverageOutperform$35.00Low
3/22/2022GuggenheimDowngradeBuy ➝ NeutralHigh
3/14/2022WedbushReiterated RatingNeutralMedium
3/7/2022WedbushLower TargetNeutral$35.00 ➝ $33.00High
3/7/2022HC WainwrightBoost TargetBuy$43.00 ➝ $46.00Medium
10/26/2021HC WainwrightReiterated RatingBuy$44.00Low
10/26/2021WedbushBoost TargetNeutral$25.00 ➝ $32.00Low
10/4/2021HC WainwrightReiterated RatingBuy$43.00High
9/27/2021HC WainwrightReiterated RatingBuy$43.00Low
8/18/2021WedbushBoost TargetPositive ➝ Neutral$20.00 ➝ $25.00High
8/10/2021HC WainwrightReiterated RatingBuy$43.00Low
6/22/2021HC WainwrightInitiated CoverageBuy$43.00High
5/20/2021UBS GroupInitiated CoverageNeutral$29.00Low
3/16/2021Truist FinancialUpgradeHold ➝ Buy$27.00 ➝ $34.00Low
3/15/2021WedbushReiterated RatingOutperform ➝ NeutralN/A
3/9/2021WedbushDowngradeOutperform ➝ NeutralMedium
3/8/2021JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightHigh
2/11/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Overweight$19.00 ➝ $40.00Low
10/27/2020Truist FinancialBoost Target$20.00 ➝ $27.00High
10/27/2020WedbushUpgradeNeutral ➝ Outperform$20.00 ➝ $35.00High
10/14/2020Truist FinancialBoost Target$16.00 ➝ $20.00High
10/14/2020GuggenheimUpgradeNeutral ➝ Buy$36.00High
5/7/2020Credit Suisse GroupBoost TargetNeutral$14.00 ➝ $16.00High
5/6/2020Stifel NicolausReiterated RatingHold$17.00Low
3/3/2020SunTrust BanksLower TargetHold$15.00 ➝ $14.00High
3/2/2020Stifel NicolausReiterated RatingHold$18.00Low
11/8/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$12.00N/A
11/8/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$109.00 ➝ $17.00N/A
11/8/2019WedbushDowngradeOutperform ➝ NeutralN/A
11/8/2019GuggenheimDowngradeBuy ➝ NeutralN/A
11/8/2019SunTrust BanksDowngradeBuy ➝ HoldN/A
10/3/2019Credit Suisse GroupLower TargetNeutral$75.00 ➝ $48.00Low
10/1/2019WedbushReiterated RatingOutperformHigh
9/30/2019Stifel NicolausReiterated RatingHoldHigh
8/20/2019Cantor FitzgeraldSet TargetBuy$140.00High
8/12/2019Stifel NicolausSet TargetHold$63.00Medium
8/9/2019Credit Suisse GroupLower TargetNeutral$79.00 ➝ $75.00High
6/24/2019HC WainwrightSet TargetBuy$126.00High
6/24/2019SunTrust BanksLower TargetBuy$125.00 ➝ $93.00High
(Data available from 6/24/2019 forward)

News Sentiment Rating

1.25 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/25/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 7 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/25/2024
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
AnaptysBio logo
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Read More

Today's Range

Now: $24.00
Low: $23.17
High: $24.62

50 Day Range

MA: $23.49
Low: $18.87
High: $26.58

52 Week Range

Now: $24.00
Low: $13.36
High: $27.50

Volume

1,223,900 shs

Average Volume

335,803 shs

Market Capitalization

$655.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of AnaptysBio?

The following Wall Street research analysts have issued stock ratings on AnaptysBio in the last twelve months: BTIG Research, JPMorgan Chase & Co., Leerink Partnrs, Piper Sandler, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, UBS Group AG, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for ANAB.

What is the current price target for AnaptysBio?

8 Wall Street analysts have set twelve-month price targets for AnaptysBio in the last year. Their average twelve-month price target is $46.38, suggesting a possible upside of 93.2%. Piper Sandler has the highest price target set, predicting ANAB will reach $80.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $21.00 for AnaptysBio in the next year.
View the latest price targets for ANAB.

What is the current consensus analyst rating for AnaptysBio?

AnaptysBio currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ANAB.

What other companies compete with AnaptysBio?

How do I contact AnaptysBio's investor relations team?

AnaptysBio's physical mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 362-6295 and its investor relations email address is [email protected]. The official website for AnaptysBio is www.anaptysbio.com. Learn More about contacing AnaptysBio investor relations.